Mylan Looks To Expedite Biosimilar Humira in EU Through Kyowa Deal
Executive Summary
Mylan has acquired commercial rights in Europe to Kyowa Hakko Kirin's biosimilar adalimumab, paving the way to an early market entry through the product, which could be approved in the second half of this year. But might there be a shift in the commercialization outlook for its partnered adalimumab with Biocon?
You may also be interested in...
Toujeo, Perjeta Biosimilars On Biocon-Mylan Menu But Humira Version Iffy
Biocon is building on its alliance with Mylan and the partners are adding biosimilar programs for insulin glargine 300 units/mL and pertuzumab to their pipeline. But there's little clarity on the duo's ongoing program for biosimilar adalimumab in the backdrop of Mylan's recent deal with Fujifilm Kyowa Kirin Biologics for its product.
Toujeo, Perjeta Biosimilars On Biocon-Mylan Menu But Humira Version Iffy
Biocon is building on its alliance with Mylan and the partners are adding biosimilar programs for insulin glargine 300 units/mL and pertuzumab to their pipeline. But there's little clarity on the duo's ongoing program for biosimilar adalimumab in the backdrop of Mylan's recent deal with Fujifilm Kyowa Kirin Biologics for its product.
Deal Watch Asia Focus: Pfenex Licenses Asian Rights To Forteo Copy To NT Pharma Group
Otsuka obtains Japanese rights to two cancer gene therapy candidates from Takara. GlaxoSmithKline extends its protein degradation collaboration with Kymera.